Our previous work demonstrated that CML stem and progenitor cells that are TKI-resistant, but lack BCR-ABL1 kinase domain mutations, are dependent on STAT3 and susceptible to STAT3 inhibition [19, 20]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.